Oliva, a healthtech platform offering specialist, on-demand mental health and wellbeing support to employees, has announced a €5 million fundraise in a round led by Molten Ventures and joined by existing investors Stride VC and new backers Alumni Ventures. Angels including Kieran Flanagan, CMO at Zapier, also participated.  

Manus that it has closed a £2.6m funding round to support the commercialisation of its innovative NeuroMotor Pen™.

Existing investors supported the £2.6m investment round including the North East Innovation Fund, supported by the European Regional Development Fund, and managed by Northstar Ventures coleading the round with Par Equity with participation from SIS Ventures, Scottish Enterprise and Old College Capital.

South East Angels investment ORB Innovations has been cquired by Glidewell Dental, one of the largest dental companies in the world.

Grow Lab Organics (GLO), a British cannabis company headquartered in the Isle of Man, has closed a £1m seed round from investors including Saul Milton (Chase & Status) and Mark Wilkinson. With the first commercial cannabis licence on the island, and one of the first in the UK, GLO is now launching a community offer to become the first community-owned medicinal cannabis producer in Europe, enabling patients to live better lives through the power of cannabis.

Clinical trials of an easy-to-use home therapeutic treatment for SARS-CoV-2 (coronaviruses), developed by Cardiff based Halo Therapeutics, are underway following a £1.5 million investment led by the Development Bank of Wales alongside Science Angel Syndicate (SAS) members and the KBA Group. 

SWEDEN: The Swedish health tech company Encare has secured funding of EUR 1.5 million to support the company's continued expansion, product development, and entrance into new international markets. Encare's SaaS solution supports healthcare providers in implementing best practices for surgical care to improve patient outcomes. Existing shareholders, together with some new, through the Sciety network, took part in the financing round. 

Following its latest funding round, Rosa Biotech has announced plans to accelerate development of its pioneering bio-sensing technology, designed to enable cost effective screening of a range of life-threatening diseases with high accuracy at an early stage.

SOLASTA Bio, a UK agritech specialising in the next generation of green insecticides has secured a further round of investment totalling £4 million to scale up the development of its unique nature-inspired pesticides, the first of their kind to be developed worldwide.

Oxford Innovation EIS Growth Fund alongside OION angel investors, have invested in the £1.2 million oversubscribed funding round for OSSTEC, the orthopaedics company developing bone healing implants.

Its patented platform technology, proven over 8 years of research and development at Imperial College London, reduces implant loosening and bone loss post-surgery. OSSTEC’s world leading team combining engineers and surgeons, has developed the first fully porous implants to stimulate long-term bone growth.

A Newcastle-based company has raised over £ 1.85 million of funding to help its quest to save more lives through better testing for prostate cancer.

The funding includes £500,000 investment from the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures alongside investment from Prostate Cancer Research together with and investment of £250,000 from JR Holding ASI, and £305,000 from angel investors. On top of this investment Innovate UK awarded the company a grant of £750,000 to develop its disease screening activities.

The SABI has successfully closed its pre-seed investment round, securing €150,000 from a group of industry focused investors. 

QV Bioelectronics, creators of an innovative surgically implanted Electric Field Therapy (EFT) device for the treatment of brain tumours, has been awarded a £860,000 grant under the Combined Investor Partnerships Award. This follow a successful £2m Pre-Series A fundraising round in January 2023, which included a number of angel investors. 

The award from Innovate UK takes the total amount of grant funding awarded to QV to £1.8m, which includes an ongoing Innovate UK Biomedical Catalyst Award and previous support from the National Institute for Health Research (NIHR) and Innovate UK SMART.